Halozyme Therapeutics, Inc. reiterating its financial guidance for 2022, which was last provided on August 9, 2022 as a result of the close of the Antares Pharma transaction and strong year-to-date results. For the full year 2022, the Company expects: total revenue of $655 million to $685 million, representing growth of 48% to 55% over 2021 total revenue primarily driven by projected revenue contribution from the Antares business of $115 million to $125 million; GAAP operating income of $240 million to $265 million, which includes one-time transaction costs of approximately $45 million and amortization of approximately $80 million related to the Antares acquisition; GAAP net income of $170 million to $195 million; GAAP diluted earnings per share of $1.20 to $1.35 due to acquisition related costs in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.82 USD | -0.23% | -2.56% | +18.56% |
May. 22 | Halozyme Therapeutics Insider Sold Shares Worth $905,480, According to a Recent SEC Filing | MT |
May. 07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.56% | 5.58B | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-0.29% | 21.78B | |
-9.28% | 18.09B | |
-41.70% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022